If you entered a web address please check it was correct.
\nYou can also try Search Page to find the study you are looking for.
"}}},"trialDetailsJson":{"title":"Details Page","returnSearch":"Back to search results","description":"Study Description","identifier":"ViiV Study ID","clinicalID":"Clinicaltrials.gov Identifier","EudraCtID":"EudraCT Number","resultsAvailable":"Has Results Available Below","docAvailable":"Has Results Document Available","studyOverview":"Study Overview","overviewSection":{"conditionsDisplay":"Medical Conditions","product":"Product","collaborators":"Collaborators","dates":"Date","studyType":"Type","phase":"Phase","gender":"Gender","age":"Age","acceptVolunteers":"Accepts Healthy Volunteers"},"studyDocuments":"Study Documents","noDocuments":"No documents available","studyDocumentsAdditionalText":"If you wish to request for Full Study Report, please contact - ","studyDocumentsAdditionalEmail":"GSKClinicalSupportHD@gsk.com","isReleased":{"firstPart":"This study has Protocol and Result summary on ClinicalTrial.gov. Click","secondPart":"to learn more.","linkText":"here"},"mapLocations":"Locations","centralContact":"Central Contact","centralPhone":"Central Contact Phone","centralEmail":"Central Contact Email","mapSection":{"site":"GSK Investigational Site","condition":"Condition","id":"Study ID","city":"City","state":"State","zip":"Zip","country":"Country"},"studyDesign":"Study Design","designSection":{"purpose":"Primary Purpose","allocation":"Allocation","study_design":"Study Design","study_classification":"Study Classification","masking":"Masking","masked_subject":"Masked Subject","masked_caregiver":"Masked Caregiver","masked_investigator":"Masked Investigator","masked_assessor":"Masked Assessor","primary_outcomes":"Primary Outcomes","secondary_outcomes":"Secondary Outcomes","arms":"Arms","interventions":"Interventions","keyword":"Keyword","inclusionTitle":"Inclusion Criteria","exclusionTitle":"Exclusion Criteria","criteriaText":"Inclusion/Exclusion Criteria","criteria_button":"Click to view inclusion/exclusion criteria","enrollment":"Enrollment","clinicalPublications":"Clinical Publications"},"popoversText":{"studyId":{"childMarkdownRemark":{"html":"A unique number for a study given by ViiV.
"}},"ctGov":{"childMarkdownRemark":{"html":"This number identifies the study on the US clinicaltrials.gov register. Click this link to go to the entry for this study on Clinicaltrials.gov where you will be able to see protocol and results summaries where available.
"}},"eudraCT":{"childMarkdownRemark":{"html":"This number identifies the study on the EU clinicaltrials.eu register. Click this link to go to the entry for this study on clinicaltrials.eu where you will be able to see protocol and results summaries where available.
"}}}},"site":{"siteMetadata":{"siteUrl":"https://www.viiv-studyregister.com"}},"studyDetails":{"nct_number":"NCT02478632","ctis_id":"","HasResults":"true","IpdAccessCriteria":"","IpdDescription":"","IpdInfoTypeAnalyticCode":"","IpdInfoTypeIcf":"","IpdInfoTypeCsr":"","IpdInfoTypeProtocol":"","IpdInfoTypeSap":"","IpdTimeFrame":"","IpdUrl":"http://","IsFlexibleTrial":false,"IsReleasedToCtGov":"true","MaskingInfo":{"masked_assessor":"false","masked_caregiver":"false","masked_investigator":"false","masked_subject":"false","masking_description":"","no_masking":"true"},"PatientLevelData":"false","SharingIpd":"None","acronym":"","allocation":"Non-randomized","arm_groups":[{"arm_group_label":"CAR","arm_group_description":"Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2).","arm_type":"Active Comparator"},{"arm_group_label":"DTG 50 mg + RPV 25 mg","arm_group_description":"Participants do not receive study medication in this study 202094. Participants group carried over from the parent study 201636 (SWORD-1) or 201637 (SWORD-2)","arm_type":"Experimental"}],"assignment":"Parallel Assignment","brief_summary":"The purpose of this study is to evaluate any change from baseline in bone mineral density (BMD) in subjects following the switch from a triple antiretroviral therapy (ART) regimen containing Tenofovir disoproxil fumarate (TDF) to the nucleoside reverse transcriptase inhibitor (NRTI) – sparing two – drug regimen of dolutegravir (DTG) + rilpivirine (RPV) in subjects participating in the parent studies 201636 and 201637 (SWORD-1 and SWORD-2). This open-label, parallel group, study is a sub-study which will recruit subjects who are receiving ART regimens which include TDF at the time of randomization to receive treatment in one of two identical parent studies 201636 and 201637 (SWORD-1 and SWORD-2). These are Phase III, randomised, open-label, multicentre, parallel-group, non-inferiority studies evaluating the efficacy, safety, and tolerability of switching to DTG plus RPV from current integrase inhibitor (INI)-, non NNRTI-, or protease inhibitor (PI)-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed, having HIV-1 ribonucleic acid (RNA) levels <50 copies per millilitre (c/mL). Randomisation in the parent studies will be stratified by baseline third agent class (INI, NNRTI, or PI), age group (< or =>50 years old) and participation in this Dual energy X-ray absorptiometry (DEXA) sub-study, therefore there will also be balance across the treatment arms in this sub-study both overall and with respect to baseline third agent class and age at entry. The study population will include approximately 75 evaluable subjects recruited from the Early Switch DTG + RPV treatment group of the parent studies 201636 and 201637, and approximately 75 evaluable subjects from the Late Switch group who continue their current antiretroviral therapy (CAR) through to Week 52 across both the 201636 and 201637 (SWORD-1 and SWORD-2) studies. Subjects participating in study 202094 will have DEXA scans performed at Day 1 and at study Weeks 48, 100 and 148 in parallel with the corresponding scheduled visits in the parent studies.","brief_summary_OneLinkTx":"","brief_title_OneLinkTx":"","brief_title":"Bone mineral density in human immunodeficiency virus type 1 (HIV-1)-infected adult subjects switching from a tenofovir regimen to a dolutegravir plus rilpivirine regimen","conditions":[{"DisplayValue":"Human Immunodeficiency Virus (HIV)","DisplayValue_OneLinkTx":"","InternalValue":"CON_HIV","LookupValue":"Infection, Human Immunodeficiency Virus","LookupValue_OneLinkTx":""}],"created_date":"09/15/2018 17:28:43","criteria":"Inclusion Criteria: - Screened and eligible but not yet randomised to either of the parent studies 201636 (SWORD-1) or 201637 (SWORD-2) - Receiving an ART regimen which contains TDF - Female subjects of child bearing potential with a negative pregnancy test at both Screening and Day 1 and agrees to use one of the methods of contraception described in the protocols of the parent studies 201636 (SWORD-1) and 201637 (SWORD-2) to avoid pregnancy. Any contraception method must be used consistently, throughout the study period in accordance with the approved product label, including adherence to appropriate ‘run in‘ periods for hormonal contraception - Subject is willing and able to understand the requirements of study participation and provide signed and dated written informed consent prior to Screening. Subject is considered an appropriate candidate for participation in this study - For subjects enrolled in France: a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category Exclusion Criteria: - Less than three vertebra in the range of L1 to L4 that are suitable for BMD measurement by DEXA scan - Bilateral hip replacement - Uncontrolled thyroid disease: thyroid stimulating hormone (TSH) above normal range, and considered to indicate a requirement for thyroid replacement therapy - Male hypogonadism: serum testosterone < 300 nanogram per decilitre (ng/dL) on a sample collected before 10:00 in the morning and the subject is able and willing to start testosterone replacement therapy - Endocrine diseases including Cushing’s syndrome and diabetes mellitus - History of fragility fractures - Ever treated for osteoporosis with bisphosphonates, oestrogen receptor modulators or other therapies, and / or severe osteoporosis as indicated by a prior DEXA scan derived T-score of -3.5 or lower value - Body mass index (BMI) < 18 kilogram per meter (kg/m)^2 or =>40 kg/m^2 - Vitamin D deficiency: 25 Hydroxy Vitamin D < 15ng/mL - Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the investigator, may interfere with the subject’s ability to comply with the scheduled protocol evaluations or which may compromise the safety of the subject - Current use or intent to initiate, tamoxifen, bone-related treatment, e.g. biphosphonates, osteoporosis medications including selective oestrogen receptor modulator medicines (raloxifene, arzoxifene and lasofoxifene), growth hormone or anabolic steroids, except for testosterone as specified below, during the study period - The following are excluded unless they have been given for at least 6 months prior to Day 1, and there is no plan to stop them during the study: Anti-convulsant therapy and hormonal therapy, including female hormone replacement therapy or testosterone as a replacement therapy or supplement - Women who are pregnant, breastfeeding or who plan to become pregnant or breast feed during the study period - Subject enrolled, or anticipated to be selected to participate following study registration, in an investigational clinical protocol/s in addition to one of the parent studies 201636 or 201637 (SWORD-1 or SWORD-2)","detailed_description":"","display_gender":"Both","display_gender_internal":"GENDER_ALL","display_phase":"Phase 3","display_phase_internal":"PHASE_3","display_status":"Active, not recruiting","display_status_internal":"RECSTATUS_I_ACTIVE_NOT_REC","endpoint":"","enrollment":"102","exclusion":"","gender":"All","gender_based":"","gender_description":"","healthy_volunteers":"No","id":"19b87298-1abf-5b7a-b3da-8b0d6da48d34","internal":{"content":null,"contentDigest":"bade8c0b8e5aec516eaf17d1f2c06a8e","description":null,"fieldOwners":null,"mediaType":null,"ignoreType":null,"owner":"default-site-plugin","type":"studyDetails"},"inclusion":"Inclusion Criteria: - Screened and eligible but not yet randomised to either of the parent studies 201636 (SWORD-1) or 201637 (SWORD-2) - Receiving an ART regimen which contains TDF - Female subjects of child bearing potential with a negative pregnancy test at both Screening and Day 1 and agrees to use one of the methods of contraception described in the protocols of the parent studies 201636 (SWORD-1) and 201637 (SWORD-2) to avoid pregnancy. Any contraception method must be used consistently, throughout the study period in accordance with the approved product label, including adherence to appropriate ‘run in‘ periods for hormonal contraception - Subject is willing and able to understand the requirements of study participation and provide signed and dated written informed consent prior to Screening. Subject is considered an appropriate candidate for participation in this study - For subjects enrolled in France: a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category Exclusion Criteria: - Less than three vertebra in the range of L1 to L4 that are suitable for BMD measurement by DEXA scan - Bilateral hip replacement - Uncontrolled thyroid disease: thyroid stimulating hormone (TSH) above normal range, and considered to indicate a requirement for thyroid replacement therapy - Male hypogonadism: serum testosterone < 300 nanogram per decilitre (ng/dL) on a sample collected before 10:00 in the morning and the subject is able and willing to start testosterone replacement therapy - Endocrine diseases including Cushing’s syndrome and diabetes mellitus - History of fragility fractures - Ever treated for osteoporosis with bisphosphonates, oestrogen receptor modulators or other therapies, and / or severe osteoporosis as indicated by a prior DEXA scan derived T-score of -3.5 or lower value - Body mass index (BMI) < 18 kilogram per meter (kg/m)^2 or =>40 kg/m^2 - Vitamin D deficiency: 25 Hydroxy Vitamin D < 15ng/mL - Any pre-existing physical or mental condition (including substance abuse disorder) which, in the opinion of the investigator, may interfere with the subject’s ability to comply with the scheduled protocol evaluations or which may compromise the safety of the subject - Current use or intent to initiate, tamoxifen, bone-related treatment, e.g. biphosphonates, osteoporosis medications including selective oestrogen receptor modulator medicines (raloxifene, arzoxifene and lasofoxifene), growth hormone or anabolic steroids, except for testosterone as specified below, during the study period - The following are excluded unless they have been given for at least 6 months prior to Day 1, and there is no plan to stop them during the study: Anti-convulsant therapy and hormonal therapy, including female hormone replacement therapy or testosterone as a replacement therapy or supplement - Women who are pregnant, breastfeeding or who plan to become pregnant or breast feed during the study period - Subject enrolled, or anticipated to be selected to participate following study registration, in an investigational clinical protocol/s in addition to one of the parent studies 201636 or 201637 (SWORD-1 or SWORD-2)","interventions":[{"arm_group_label":"CAR","intervention_description":"Participants do not receive study medication in this study 202094.","intervention_name":"Subjects do not receive study medication in this study 202094","intervention_type":"Drug"},{"arm_group_label":"DTG 50 mg + RPV 25 mg","intervention_description":"Participants do not receive study medication in this study 202094.","intervention_name":"Subjects do not receive study medication in this study 202094","intervention_type":"Drug"}],"interventional_subtype":"Treatment","is_fda_regulated":true,"is_high_value":false,"is_ind_study":true,"keywords":["tenofovir disoproxil fumarate","dolutegravir plus rilpivirine","two-drug regimen","bone mineral density","dual energy X-ray absorptiometry (DEXA)","Human Immunodeficiency Virus-1","nucleoside reverse transcriptase inhibitor -sparing regimen","integrase inhibitor"],"last_follow_up_date":"08/17/2018 00:00:00","links":[],"locations":[{"City":"Buenos Aires","Latitude":"-34.6213576","CountryDisplay":"Argentina","Longitude":"-58.3773266","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"1141","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Alicante","Latitude":"38.3616509","CountryDisplay":"Spain","Longitude":"-0.489172","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"03010","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Toronto","Latitude":"43.6584136","CountryDisplay":"Canada","Longitude":"-79.3891419","Name":"GSK Investigational Site","StateDisplay":"Ontario","PostalCode":"M5G 2N2","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Cartagena (Murcia)","Latitude":"37.5867941","CountryDisplay":"Spain","Longitude":"-0.9677301","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"30202","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Montreal","Latitude":"45.50071","CountryDisplay":"Canada","Longitude":"-73.574572","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"H3A 1T1","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Madrid","Latitude":"40.4473608","CountryDisplay":"Spain","Longitude":"-3.7384311","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28040","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Los Angeles","Latitude":"34.0664817","CountryDisplay":"United States","Longitude":"-118.3520389","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90036","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Liege","Latitude":"50.6350757","CountryDisplay":"Belgium","Longitude":"5.5628874","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"4000","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Kansas City","Latitude":"39.0587452","CountryDisplay":"United States","Longitude":"-94.5985613","Name":"GSK Investigational Site","StateDisplay":"Missouri","PostalCode":"64111","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Madrid","Latitude":"40.3672276","CountryDisplay":"Spain","Longitude":"-3.6978264","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28041","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Beverly Hills","Latitude":"34.0661071","CountryDisplay":"United States","Longitude":"-118.3841777","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90211","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Barcelona","Latitude":"41.4264213","CountryDisplay":"Spain","Longitude":"2.1401139","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08035","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Ciudad Autonoma de Buenos Aires","Latitude":"-34.6036844","CountryDisplay":"Argentina","Longitude":"-58.3815591","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"C1425AWK","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Phoenix","Latitude":"33.5079722","CountryDisplay":"United States","Longitude":"-112.1012912","Name":"GSK Investigational Site","StateDisplay":"Arizona","PostalCode":"85015","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Québec","Latitude":"46.7691394","CountryDisplay":"Canada","Longitude":"-71.2832751","Name":"GSK Investigational Site","StateDisplay":"Québec","PostalCode":"G1V 4G2","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Vancouver","Latitude":"49.278915","CountryDisplay":"Canada","Longitude":"-123.12909","Name":"GSK Investigational Site","StateDisplay":"British Columbia","PostalCode":"V6Z 2C7","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Orlando","Latitude":"28.5542151","CountryDisplay":"United States","Longitude":"-81.3454417","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"32803","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"London","Latitude":"51.5190259","CountryDisplay":"United Kingdom","Longitude":"-0.058075","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"E1 1BB","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Palma de Mallorca","Latitude":"39.583881","CountryDisplay":"Spain","Longitude":"2.7232456","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"07198","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Houston","Latitude":"29.7333171","CountryDisplay":"United States","Longitude":"-95.417519","Name":"GSK Investigational Site","StateDisplay":"Texas","PostalCode":"77098","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Málaga","Latitude":"36.7226027","CountryDisplay":"Spain","Longitude":"-4.467102","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"29010","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Bruxelles","Latitude":"50.8427501","CountryDisplay":"Belgium","Longitude":"4.3515499","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"1000","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"London","Latitude":"51.5531762","CountryDisplay":"United Kingdom","Longitude":"-0.1652792","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"NW3 2QG","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Gent","Latitude":"51.0678307","CountryDisplay":"Belgium","Longitude":"3.7290914","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"9000","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Madrid","Latitude":"40.4731818","CountryDisplay":"Spain","Longitude":"-3.6864121","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"28046","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Lynchburg","Latitude":"37.4137536","CountryDisplay":"United States","Longitude":"-79.1422464","Name":"GSK Investigational Site","StateDisplay":"Virginia","PostalCode":"24501","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Sevilla","Latitude":"37.3552204","CountryDisplay":"Spain","Longitude":"-5.9673967","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"41013","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"San Francisco","Latitude":"37.7929789","CountryDisplay":"United States","Longitude":"-122.4212424","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"94109","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Barcelona","Latitude":"41.3494786","CountryDisplay":"Spain","Longitude":"2.1033017","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08907","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Miami","Latitude":"25.7307897","CountryDisplay":"United States","Longitude":"-80.2377078","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33133","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Omaha","Latitude":"41.2552541","CountryDisplay":"United States","Longitude":"-95.9796225","Name":"GSK Investigational Site","StateDisplay":"Nebraska","PostalCode":"68198","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Ciudad de Buenos Aires","Latitude":"-34.6036844","CountryDisplay":"Argentina","Longitude":"-58.3815591","Name":"GSK Investigational Site","StateDisplay":"Buenos Aires","PostalCode":"C1202ABB","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Rosario","Latitude":"-32.9622313","CountryDisplay":"Argentina","Longitude":"-60.6255364","Name":"GSK Investigational Site","StateDisplay":"Santa Fe","PostalCode":"2000","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Murcia","Latitude":"37.9850434","CountryDisplay":"Spain","Longitude":"-1.1221111","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"30003","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Badalona","Latitude":"41.474766","CountryDisplay":"Spain","Longitude":"2.2285864","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"08916","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"St. Louis","Latitude":"38.647459","CountryDisplay":"United States","Longitude":"-90.25731","Name":"GSK Investigational Site","StateDisplay":"Missouri","PostalCode":"63108","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"Chapel Hill","Latitude":"35.9722081","CountryDisplay":"United States","Longitude":"-79.0475559","Name":"GSK Investigational Site","StateDisplay":"North Carolina","PostalCode":"27514","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Washington","Latitude":"38.9156487","CountryDisplay":"United States","Longitude":"-77.0737149","Name":"GSK Investigational Site","StateDisplay":"District of Columbia","PostalCode":"20007","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"},{"City":"Los Angeles","Latitude":"34.0931603","CountryDisplay":"United States","Longitude":"-118.3783347","Name":"GSK Investigational Site","StateDisplay":"California","PostalCode":"90069","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Seattle","Latitude":"47.6015566","CountryDisplay":"United States","Longitude":"-122.3323351","Name":"GSK Investigational Site","StateDisplay":"Washington","PostalCode":"98104","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"London","Latitude":"51.4680061","CountryDisplay":"United Kingdom","Longitude":"-0.0956074","Name":"GSK Investigational Site","StateDisplay":null,"PostalCode":"SE5 9RJ","StatusDisplay":"Terminated","StatusDisplayInternal":"LOCSTATUS_TERMINATED","StatusMapped":"Terminated/Withdrawn"},{"City":"Vancouver","Latitude":"49.2789524","CountryDisplay":"Canada","Longitude":"-123.1249804","Name":"GSK Investigational Site","StateDisplay":"British Columbia","PostalCode":"V6Z 2T1","StatusDisplay":"Recruiting","StatusDisplayInternal":"LOCSTATUS_RECRUITING","StatusMapped":"Recruiting"},{"City":"West Palm Beach","Latitude":"26.7153474","CountryDisplay":"United States","Longitude":"-80.0533253","Name":"GSK Investigational Site","StateDisplay":"Florida","PostalCode":"33401","StatusDisplay":"Completed","StatusDisplayInternal":"LOCSTATUS_COMPLETED","StatusMapped":"Study Complete"}],"masking":"","maximum_age_raw":"N/A","maximum_age":"N/A","minimum_age":"18","minimum_age_raw":"18 years","modified_date":"10/01/2018 22:37:56","number_of_arms":"2","observational_design":{"biospecimen_description":"","biospecimen_retention":"","number_of_groups":"","observational_study_design":"","patient_registry":"","target_duration_quantity":"","target_duration_units":"","timing":""},"official_title":"An evaluation of bone mineral density in HIV-1-infected adult subjects switching from a tenofovir-containing antiretroviral therapy regimen to a dolutegravir plus rilpivirine regimen","org_study_id":"202094","overall_contact":{"email":"GSKClinicalSupportHD@gsk.com","last_name":"Call Center","phone":"877-379-3718"},"overall_status":"Active, not recruiting - Interventional","oversight_info":{"exported_from_us":"","fda_regulated_device":"","fda_regulated_drug":"","ped_postmarket_surv":"","has_dmc":false,"post_prior_to_approval":"","regulatory_authorities":[""]},"phase":"3","primary_compl_date":"09/16/2016 00:00:00","primary_outcomes":[],"product_name":"","product_name_OneLinkTx":"","secondary_ids":[],"secondary_outcomes":[{"outcome_description":null,"outcome_measure":null,"outcome_time_frame":null,"outcome_safety_issue":null}],"sponsors":{"investigator_affiliation":"","investigator_username":"","lead_sponsor":"ViiV Healthcare","collaborators":["Janssen Pharmaceuticals","GlaxoSmithKline"]},"start_date":"06/01/2015 00:00:00","study_type":"Interventional","therapeutic_area":"Infectious Diseases","citations":[],"is_section_801":true}},"pageContext":{"studyId":"202094"}},"staticQueryHashes":["162689979","3332233851","3729204765","3769354840","399703114"]}